TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Salarius Pharmaceuticals ( (SLRX) ) just unveiled an announcement.
On November 11, 2025, Salarius Pharmaceuticals announced an underwritten public offering of approximately $7 million, involving common stock and various warrants, with Ladenburg Thalmann & Co. Inc. as the sole underwriter. The offering closed on November 12, 2025, raising net proceeds of around $6.3 million, which will be used to advance clinical development, pay off Decoy Therapeutics’ promissory notes, and for general corporate purposes. Concurrently, Salarius completed a merger with Decoy Therapeutics, making it a wholly-owned subsidiary, and appointed new executives, including Frederick E. Pierce as CEO. This strategic move aims to strengthen Salarius’ market position and expand its research capabilities.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatment options for cancer patients. Its product portfolio includes seclidemstat, currently in a Phase 1/2 clinical study for hematologic cancers, and SP-3164, an oral small molecule protein degrader. The company has received financial support from the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.
Average Trading Volume: 1,566,610
Technical Sentiment Signal: Sell
Current Market Cap: $1.21M
Learn more about SLRX stock on TipRanks’ Stock Analysis page.